SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Lizzie Tudor who wrote (83199)11/4/1999 7:19:00 PM
From: Bob Kim  Read Replies (1) | Respond to of 164687
 
Do you mean Blodget gets special consideration somehow?

I would say so. Look at Shilakes, he raised his price target on ARBA from $140 to $205 after earnings. He recently raised his price target on ORCL (he'll have to do it again it looks like). Sometimes, price targets are raised much to an analyst's surprise (without their explicit knowledge).

As far as I know, Blodget still has ETYS @50, SWCM @60, ICGE @125.



To: Lizzie Tudor who wrote (83199)11/5/1999 5:58:00 AM
From: Olu Emuleomo  Respond to of 164687
 
>>>I think Blodget is good with b2c, but somehow I don't believe he gets the b2b
space, <<<

No, he does not! This group escaped him entirely! Also Mary Meeker flubbed this group too, I believe.
I did not hear any 'guru' analyst give us a heads up on the B2B group! If any did, pls someone tell us.

--Olu E.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News